866-997-4948(US-Canada Toll Free)

Neuroblastoma - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Feb 2013

Category :

Oncology

No. of Pages : 139 Pages


Global Markets Directs, \'Neuroblastoma - Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Neuroblastoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neuroblastoma. 

Neuroblastoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Neuroblastoma.
  • A review of the Neuroblastoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Neuroblastoma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Neuroblastoma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Neuroblastoma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Neuroblastoma Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Neuroblastoma 8
Neuroblastoma Therapeutics under Development by Companies 10
Neuroblastoma Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Discovery and Pre-Clinical Stage Products 18
Comparative Analysis 18
Neuroblastoma Therapeutics - Products under Development by Companies 19
Neuroblastoma Therapeutics - Products under Investigation by Universities/Institutes 21
Companies Involved in Neuroblastoma Therapeutics Development 23
United Therapeutics Corporation 23
Novartis AG 24
Chugai Pharmaceutical Co. Ltd 25
Enzon Pharmaceuticals, Inc. 26
AEterna Zentaris Inc. 27
Lixte Biotechnology Holdings, Inc. 28
Molecular Insight Pharmaceuticals, Inc. 29
Sareum Holdings plc 30
MabVax Therapeutics, Inc. 31
Avaris 32
Bionucleon Srl 33
Neotropix, Inc. 34
APEIRON Biologics AG 35
Archer Biosciences, Inc 36
ipal GmbH 37
Errant Gene Therapeutics, LLC 38
CellAct Pharma GmbH 39
Neuroblastoma - Therapeutics Assessment 40
Assessment by Monotherapy Products 40
Assessment by Combination Products 41
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Drug Profiles 47
perifosine - Drug Profile 47
APN-301 - Drug Profile 50
PEG-SN38 - Drug Profile 51
NTX-010 - Drug Profile 53
Chk-1 Inhibitor Programme - Drug Profile 55
iobenguane I 131 - Drug Profile 56
edotreotide - Drug Profile 57
3F8-Mab - Drug Profile 59
bortezomib + irinotecan hydrochloride - Drug Profile 60
DFMO + Etoposide - Drug Profile 61
X-396 - Drug Profile 63
irinotecan hydrochloride + sorafenib tosylate - Drug Profile 64
lexatumumab - Drug Profile 65
lexatumumab - Drug Profile 66
Aldesleukin Gene Modified Tumor Cell Vaccine - Drug Profile 67
vorinostat + 131-I MIBG + Peripheral Blood Stem Cell Transplant - Drug Profile 68
bevacizumab + [cyclophosphamide] + [zoledronic acid] - Drug Profile 70
eflornithine hydrochloride - Drug Profile 72
Tumor Cell B Lymphoblastoid Cell Line Vaccine + [aldesleukin] - Drug Profile 73
HU14.18K322A - Drug Profile 74
Monoclonal Antibody 3F8 + [beta-glucan] - Drug Profile 75
Monoclonal antibody 3F8 + [sargramostim] - Drug Profile 76
ARC-100 + [temozolomide] - Drug Profile 77
14g2a Antibody CTLs - Drug Profile 79
Monoclonal Antibody 3F8 + [isotretinoin] + [beta-glucan] + [sargramostim] - Drug Profile 80
trabectedin + [filgrastim] + [pegfilgrastim] - Drug Profile 81
LEE-011 - Drug Profile 83
JW-1521 - Drug Profile 85
CFAKC-4 - Drug Profile 86
Netrin-1 - Drug Profile 88
Aurora Kinases + ALK Kinase Program - Drug Profile 89
Autologous Dendritic Cell Vaccine + [decitabine] + [imiquimod] - Drug Profile 90
Chimeric Monoclonal Antibody 14.18 - Drug Profile 92
Autologous Neuroblastoma Vaccine - Drug Profile 93
1-B7 - Drug Profile 94
CFAKY-15 - Drug Profile 95
APN-311 - Drug Profile 96
LB-102 - Drug Profile 98
BXQ-350 - Drug Profile 99
BN-210 - Drug Profile 101
cVE-199 - Drug Profile 102
Tri-Virus Specific Cytotoxic T-cells - Drug Profile 103
CCT-244747 - Drug Profile 105
CAP-7.1 - Drug Profile 106
P-695 - Drug Profile 108
P-1016 - Drug Profile 110
BMP4 - Drug Profile 111
MYCN-DNA Vaccine - Drug Profile 112
MCT-1 Inhibitors - Drug Profile 113
Neuroblastoma Therapeutics - Drug Profile Updates 115
Neuroblastoma Therapeutics - Discontinued Products 123
Neuroblastoma Therapeutics - Dormant Products 124
Neuroblastoma - Product Development Milestones 127
Featured News & Press Releases 127

Appendix 134
Methodology 134
Coverage 134
Secondary Research 134
Primary Research 134
Expert Panel Validation 134
Contact Us 135
Disclaimer 135

List of Table


Number of Products Under Development for Neuroblastoma, H1 2013 12
Products under Development for Neuroblastoma - Comparative Analysis, H1 2013 13
Number of Products under Development by Companies, H1 2013 15
Number of Products under Development by Companies, H1 2013 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H1 2013 18
Comparative Analysis by Late Stage Development, H1 2013 19
Comparative Analysis by Mid Clinical Stage Development, H1 2013 20
Comparative Analysis by Early Clinical Stage Development, H1 2013 21
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 22
Products under Development by Companies, H1 2013 23
Products under Development by Companies, H1 2013 (Contd..1) 24
Products under Investigation by Universities/Institutes, H1 2013 25
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 26
United Therapeutics Corporation, H1 2013 27
Novartis AG, H1 2013 28
Chugai Pharmaceutical Co. Ltd, H1 2013 29
Enzon Pharmaceuticals, Inc., H1 2013 30
AEterna Zentaris Inc., H1 2013 31
Lixte Biotechnology Holdings, Inc., H1 2013 32
Molecular Insight Pharmaceuticals, Inc., H1 2013 33
Sareum Holdings plc, H1 2013 34
MabVax Therapeutics, Inc., H1 2013 35
Avaris, H1 2013 36
Bionucleon Srl, H1 2013 37
Neotropix, Inc., H1 2013 38
APEIRON Biologics AG, H1 2013 39
Archer Biosciences, Inc, H1 2013 40
ipal GmbH, H1 2013 41
Errant Gene Therapeutics, LLC, H1 2013 42
CellAct Pharma GmbH, H1 2013 43
Assessment by Monotherapy Products, H1 2013 44
Assessment by Combination Products, H1 2013 45
Assessment by Stage and Route of Administration, H1 2013 47
Assessment by Stage and Molecule Type, H1 2013 50
Neuroblastoma Therapeutics - Drug Profile Updates 119
Neuroblastoma Therapeutics - Discontinued Products 127
Neuroblastoma Therapeutics - Dormant Products 128
Neuroblastoma Therapeutics - Dormant Products (Contd..1) 129
Neuroblastoma Therapeutics - Dormant Products (Contd..2) 130

List of Chart


Number of Products under Development for Neuroblastoma, H1 2013 12
Products under Development for Neuroblastoma - Comparative Analysis, H1 2013 13
Products under Development by Companies, H1 2013 14
Products under Investigation by Universities/Institutes, H1 2013 17
Late Stage Products, H1 2013 19
Mid Clinical Stage Products, H1 2013 20
Early Clinical Stage Products, H1 2013 21
Discovery and Pre-Clinical Stage Products, H1 2013 22
Assessment by Monotherapy Products, H1 2013 44
Assessment by Combination Products, H1 2013 45
Assessment by Route of Administration, H1 2013 46
Assessment by Stage and Route of Administration, H1 2013 47
Assessment by Molecule Type, H1 2013 48
Assessment by Stage and Molecule Type, H1 2013 49

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *